Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 3Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 27Cisplatin 17Nivolumab 14Cyclophosphamide 14Carboplatin 13Radiation 12Paclitaxel 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Cytarabine 9Vincristine 8Magnetic Resonance Spectroscopy 8Docetaxel 8Bevacizumab 8Radiosurgery 7Leucovorin 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Pemetrexed 6Irinotecan 6Injections 6Gemcitabine 6Dexamethasone 6venetoclax 5tislelizumab 5fludarabine 5enzalutamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × trastuzumab biosimilar HLX02 × 30 days × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡